ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: experimental drug JS107 enters final trial phase
Disease control Recruiting nowThis Phase 3 trial is testing an experimental drug called JS107 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after at least one prior therapy. The study will enroll about 560 participants who have a specifi…
Matched conditions: ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug HLX43 targets stomach cancer in Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial is testing an experimental drug called HLX43 in 60 people with advanced gastric or gastroesophageal junction cancer. HLX43 is a targeted therapy that delivers a potent chemotherapy agent directly to cancer cells. The study aims to find the best dose and see how…
Matched conditions: ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC